Updated antimicrobial dosing recommendations for obese patients.
Antimicrob Agents Chemother
; 68(5): e0171923, 2024 May 02.
Article
em En
| MEDLINE
| ID: mdl-38526051
ABSTRACT
The prevalence of obesity has increased considerably in the last few decades. Pathophysiological changes in obese patients lead to pharmacokinetic (PK) and pharmacodynamic (PD) alterations that can condition the correct exposure to antimicrobials if standard dosages are used. Inadequate dosing in obese patients can lead to toxicity or therapeutic failure. In recent years, additional antimicrobial PK/PD data, extended infusion strategies, and studies in critically ill patients have made it possible to obtain data to provide a better dosage in obese patients. Despite this, it is usually difficult to find information on drug dosing in this population, which is sometimes contradictory. This is a comprehensive review of the dosing of different types of antimicrobials (antibiotics, antifungals, antivirals, and antituberculosis drugs) in obese patients, where the literature on PK and possible dosing strategies in obese adults was critically assessed.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antibacterianos
/
Obesidade
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Espanha